ALS drug study halted: brain scans aimed to track inflammation
NCT ID NCT04066244
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This study looked at whether the drug BLZ945 is safe and how it affects brain inflammation in people with ALS. Researchers used special PET scans to measure immune cell activity in the brain. The study was stopped early, and it involved 28 adults with ALS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Stockholm, 14186, Sweden
-
Yale University School of Medicine
New Haven, Connecticut, 06520-8048, United States
Conditions
Explore the condition pages connected to this study.